RAPT Therapeutics (NASDAQ:RAPT) Stock Price Down 5.2%

RAPT Therapeutics, Inc. (NASDAQ:RAPTGet Rating) shares dropped 5.2% during trading on Tuesday . The company traded as low as $17.10 and last traded at $17.30. Approximately 1,204 shares changed hands during trading, a decline of 100% from the average daily volume of 356,674 shares. The stock had previously closed at $18.24.

Analysts Set New Price Targets

RAPT has been the topic of a number of research analyst reports. HC Wainwright lowered their price target on RAPT Therapeutics from $53.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, November 14th. SVB Leerink dropped their price target on shares of RAPT Therapeutics from $49.00 to $48.00 and set an “outperform” rating on the stock in a research report on Thursday, August 11th. Piper Sandler boosted their price target on shares of RAPT Therapeutics from $30.00 to $34.00 and gave the stock an “overweight” rating in a research report on Thursday, November 10th. Finally, Capital One Financial assumed coverage on shares of RAPT Therapeutics in a research report on Wednesday, September 21st. They issued an “overweight” rating and a $48.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $49.33.

RAPT Therapeutics Stock Performance

The company has a fifty day simple moving average of $22.29 and a 200-day simple moving average of $20.73.

Insiders Place Their Bets

In other RAPT Therapeutics news, insider William Ho sold 5,000 shares of the business’s stock in a transaction dated Wednesday, November 2nd. The stock was sold at an average price of $22.32, for a total transaction of $111,600.00. Following the sale, the insider now owns 47,650 shares in the company, valued at approximately $1,063,548. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders have sold 9,500 shares of company stock worth $224,965. Company insiders own 5.00% of the company’s stock.

Hedge Funds Weigh In On RAPT Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Alphabet Inc. purchased a new position in RAPT Therapeutics during the 3rd quarter valued at about $12,999,000. State Street Corp grew its stake in RAPT Therapeutics by 159.5% during the 3rd quarter. State Street Corp now owns 1,273,891 shares of the company’s stock valued at $30,650,000 after acquiring an additional 783,026 shares in the last quarter. Algert Global LLC grew its stake in RAPT Therapeutics by 18.3% during the 3rd quarter. Algert Global LLC now owns 13,677 shares of the company’s stock valued at $329,000 after acquiring an additional 2,112 shares in the last quarter. Vanguard Group Inc. grew its stake in RAPT Therapeutics by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,283,908 shares of the company’s stock valued at $30,891,000 after acquiring an additional 18,363 shares in the last quarter. Finally, Putnam Investments LLC grew its stake in RAPT Therapeutics by 9.5% during the 3rd quarter. Putnam Investments LLC now owns 21,825 shares of the company’s stock valued at $525,000 after acquiring an additional 1,901 shares in the last quarter. Hedge funds and other institutional investors own 98.42% of the company’s stock.

About RAPT Therapeutics

(Get Rating)

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Recommended Stories

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.